[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"childhood-cancer-survivors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:childhood-cancer-survivors":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,73,102,128,164,196,225,251,305,334],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100622211","impact-of-mind-body-therapies-hypnosis-and-relaxation-on-anxiety-in-children-adolescents-and-young-adults-who-had-been-treated-in-oncology-multicenter-study-100622211",false,"NCT07380672","IMpact of Mind-body Therapies (HYpnosis and Relaxation) on Anxiety in Children, Adolescents and Young Adults Who Had Been Treated in ONcology. Multicenter Study.","HARMONY-Impact","Inclusion Criteria:\n\nHARMONY KIDS\n\n* Patients aged at least 7 and under 15 at the time of inclusion, diagnosed with pediatric cancer,\n* Patients considered to be in complete remission from pediatric cancer, whose intensive treatment ended at least 3 months prior to inclusion\n* Patients receiving follow-up care after pediatric cancer at one of the participating centers,\n* Patients with anxiety disorders (SCARED-R score ≥ 31)\n* Patients affiliated with or eligible for social security,\n* Patients and their parents (or legal guardians) who have received informed consent about the study and co-signed, with the investigator, a consent form to participate in the study.\n\nHARMONY AYA\n\n* Patients aged at least 15 and no more than 25 years old at the time of inclusion, diagnosed with pediatric cancer before the age of 18,\n* Patients considered to be in complete remission from pediatric cancer, whose intensive treatment ended at least 3 months prior to inclusion,\n* Patients receiving follow-up care after pediatric cancer at one of the participating centers,\n* Patients with anxiety disorders (HADS-Anxiety score ≥ 8)\n* Patients affiliated with or eligible for social security,\n* For adult patients: patients who have received informed information about the study and have co-signed, with the investigator, a consent form to participate in the study,\n* For minors: patients and their parents (or legal guardians) who have received informed consent about the study and have co-signed, with the investigator, a consent form for participation in the study.\n\nExclusion criteria:\n\nFor HARMONY-Kids:\n\n* Presence of active suicidal ideation and\u002For need for urgent psychiatric care,\n* Patient experiencing a cancer relapse,\n* Refusal to participate,\n* Pregnant women, women in labor, or breastfeeding mothers,\n* Individuals deprived of their liberty, hospitalized without consent, or hospitalized for purposes other than research,\n* Individuals subject to legal guardianship or conservatorship, or those unable to give informed consent\n\nFor HARMONY-AYA:\n\n* Presence of active suicidal ideation and\u002For need for urgent psychiatric care,\n* Patients experiencing a cancer relapse,\n* Refusal to participate,\n* Pregnant women, women in labor, or breastfeeding mothers,\n* Individuals deprived of their liberty, hospitalized without consent, or hospitalized for purposes other than research,\n* Adults subject to legal guardianship or conservatorship, or unable to give informed consent.","ALL","7 Years","25 Years",{"count":20,"type":21},558,"ESTIMATED","INTERVENTIONAL",[24],"NA","In France today, it is estimated that one in 850 people aged between 20 and 45 has been cured of cancer in childhood. Some descriptive studies have established that cancer diagnosis and treatment can affect psychological health, with an increased risk of depression, post-traumatic stress, anxiety and suicidal risk. A French study published by our team in 2015 and 2020 also showed that, as adults, 40% of former pediatric cancer patients experienced symptoms of anxiety, a rate significantly higher than that of the general French population (25%).\n\nWhile it is well established that it is essential to detect the onset of anxiety-depressive disorders and, if necessary, to set up conventional psychological treatment (CPT), few studies have sought to show the benefit of complementing this conventional CPT with mind-body therapies (MBT) in the post-cancer pediatric setting.\n\nThis project aims to determine the benefit of mind-body therapies (hypnosis and relaxation) as a complement to conventional psychological treatment (CPT) in the management of anxiety in children, adolescents and young adults in remission from pediatric cancer or leukemia.",[27,28,29],"Adolescent Cancer Survivors","Childhood Cancer Survivors","Anxiety",[31,32,33,34,35],"childhood cancer survivor","anxiety","depression","psychology","body mind therapy","NOT_YET_RECRUITING","2026-06-17",{"date":39,"type":40},"2026-06-18","ACTUAL",{"date":42,"type":21},"2026-09-02",{"date":44,"type":21},"2028-07-01",{"name":46,"class":47},"Centre Hospitalier Universitaire de Saint Etienne","OTHER",7,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100593657","a-study-of-time-restricted-eating-in-childhood-cancer-survivors-100593657","NCT07009288","A Study of Time-Restricted Eating in Childhood Cancer Survivors","Decreasing Cardiometabolic Risk in Childhood Cancer Survivors: The STRENGTH (Survivors Engaged in Time-Restricted EatiNG After THerapy) Study","Inclusion Criteria:\n\n* Enrolled in the Childhood Cancer Survivor Study (a cohort of 5+ year survivors of childhood cancer diagnosed at age \\\u003C 21 between 1970-1999 at 31 participating institutions in North America)\n* Are ≥18 years old\n* Self-reported body mass index ≥ 25 kg\u002Fm2\n* Are not pregnant or do not intend to become pregnant in the next year\n* Stable weight over the past 3 months (+\u002F- 10 pounds)\n* If on oral medication for insulin resistance (ie, metformin), elevated blood pressure, or dyslipidemia, medication dose must be stable (ie, unchanged \\> 3 months)\n* Have internet access (can be via smartphone or computer). If neither device is available, the study can loan participants a Wi-Fi enabled device.\n\nExclusion Criteria:\n\n* Do not reside in the United States\n* Do not speak English\n* Eating window \\\u003C 12 hours per 24-hour day\n* On insulin or GLP-1 agonist\n* Diagnosis of type 1 diabetes mellitus\n* Enrolled in a formal weight management program or other weight loss trial\n* History of an eating disorder","18 Years",{"count":58,"type":21},300,[24],"This study will look at whether motivational sessions (including regular calls with a trained health coach) in combination with time-restricted eating (TRE) is an effective way to achieve weight loss and lower cardiometabolic risk in adult survivors of childhood cancer. The researchers will look at how effective this intervention is compared to the usual approach, which is to review educational materials and measure weight once a month. This study will not provide treatment for any disease or cancer.",[28],"RECRUITING","2026-05-26",{"date":65,"type":40},"2026-05-27",{"date":67,"type":40},"2025-05-27",{"date":69,"type":21},"2031-05-01",{"name":71,"class":47},"Memorial Sloan Kettering Cancer Center",4,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100634553","equol-effectiveness-study-100634553","NCT07541183","eQuoL Effectiveness Study","Conduct and Analysis of the Multi-country Effectiveness Study Within the eQuol Project","Inclusion Criteria:\n\n\\- Patients (male or female) with a history of cancer diagnosis before the age of 25 years\n\n* Patients aged between 16 and 30 years old as the study aims to primarily target digital natives who are familiar with mobile applications.\n* To be in follow-up care, completed follow-up, or lost to follow-up before inclusion at one of the institutions participating in the effectiveness study\n* Completed the planned treatment protocol\n* Without evidence of active disease and having been off therapy for at least 5 years since the first tumor diagnosis\n* Able to login and navigate phone apps\n* Sufficient language skills in one of the available study languages\n* With a valid informed consent from the patient, or, for patients younger than 18, valid consent from their parent\u002Fguardian and valid assent from the patient.\n\nExclusion Criteria:\n\nBeing unable to answer the questions of the study questionnaires (not even with help from another person) because of severe mental sequelae or insufficient mastery of the language used;\n\n● currently in treatment for secondary malignancy or relapse of primary malignancy.-","16 Years","30 Years",{"count":83,"type":21},200,"6 Months","OBSERVATIONAL","This prospective cohort study aims to evaluate the implementation and impact of the MyCare eQuoL digital tool across nine clinical sites in Europe: Italy, France, Hungary, Germany, Switzerland, Belgium, Slovenia, Spain, and Norway.\n\nMyCare eQuoL is an innovative digital tool designed to support Childhood, Adolescent and Young Adult Cancer Survivors (CAYACSs) in self-assessing their supportive care needs. Based on a built-in needs assessment, the tool provides tailored feedback including relevant information, self-management strategies, digital resources, and links to online support. It also generates a personalized needs summary to facilitate more targeted discussions with healthcare professionals. Feedback is customized through a \"content suggestion engine\" that is based on personal characteristics (e.g. age, sex, country), on the user's needs assessment, and can consider other data types as well, like the survivors' treatment history, or potential late effects.\n\nThe primary objective of the study is to assess the effectiveness of MyCare eQuoL in improving patient activation among CAYACSs across diverse European healthcare settings. Eligible participants include males and females aged 16-30 who were diagnosed with cancer before age 25, have completed their treatment at least five years prior, are currently disease-free, and have sufficient digital literacy and language proficiency to engage with the app. Exclusion criteria include severe cognitive impairments or ongoing treatment for recurrent or secondary malignancies.\n\nThe study follows a structured data collection timeline. At T0, eligible survivors are identified and invited to participate through mail or telephone. Informed consent and contact details are collected from those who agree to participate. At T1, after obtaining consent, each participant is assigned a unique study ID and attends a clinical visit (either in-person or virtual). During this visit, baseline demographic and treatment data are recorded in a secure electronic Case Report Form (eCRF). Participants are then trained to use the MyCare eQuoL app, complete the baseline questionnaires, and receive a personalized Care Plan and, where available, a digital Passport. At T2, six months post-intervention, participants receive automated reminders to complete follow-up assessments, including validated questionnaires evaluating changes in activation, quality of life, and satisfaction with the tool.\n\nThe primary outcome of the study is the change in patient activation, measured by the Patient Activation Measure (PAM) at baseline and after six months. Secondary outcomes include changes in health-related quality of life (EORTC-AYA), patient-reported experience measures (PREMs), and a cost-effectiveness evaluation. To detect a clinically meaningful 4-point difference in PAM scores, with an assumed standard deviation of 20 and Type I and II error rates of 5% and 20%, respectively, the study requires 199 participants. Accounting for a 20% dropout rate, a total of 239 participants will be recruited.\n\nPrimary outcome analysis will be conducted using multivariable logistic regression, while secondary outcomes will be analysed descriptively. Economic evaluation will include cost analysis, cost-utility analysis, and multi-criteria decision analysis.\n\nThe study will be conducted in compliance with the principles of Good Clinical Practice (ICH\u002FGCP) and the Declaration of Helsinki. The project will be registered at ClinicalTrials.gov. The research team will ensure adherence to all applicable ethical, legal, and safety regulations at both national and EU levels.",[28],[89,90,91,92],"digital tool","psychosocial support","cancer","childhood cancer survivors","2026-04-20",{"date":95,"type":40},"2026-04-23",{"date":97,"type":21},"2026-05",{"date":99,"type":21},"2027-06",{"name":101,"class":47},"Istituto Giannina Gaslini",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":56,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100562923","proof-of-concept-testing-of-the-cardiovascular-health-equity-through-food-chef-intervention-in-childhood-cancer-survivors-100562923","NCT06609473","Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors","CHEF","Inclusion Criteria:\n\n* Child with any primary cancer diagnosis (non-relapsed, non-secondary malignancy) who has received cancer-directed therapy that includes chemotherapy and\u002For radiation therapy;\n* Child is within one of the following time windows:\n\n  1. Among those receiving chemotherapy, any time from start of last planned cycle of chemotherapy until 12 months from completion of chemotherapy;\n  2. Among those receiving radiation therapy alone or radiation and surgery, any time from completion of radiation until 12 months post completion;\n* Child has 1 or more cardiovascular risk factor (defined as any of: body mass index ≥ 85th percentile; systolic or diastolic blood pressure ≥90th percentile; dyslipidemia \\[triglycerides ≥150 mg\u002FdL, total cholesterol ≥200 mg\u002FdL, LDL cholesterol ≥130 mg\u002FdL, HDL cholesterol ≤40 mg\u002FdL\\]; impaired glucose metabolism \\[fasting glucose ≥100 mg\u002FdL, hemoglobin A1c ≥5.7%\\]; anthracycline exposure ≥100 mg\u002Fm2; or any radiation exposure to chest, brain, thoracic spine, or total body);\n* Child is ≤18 years of age at time of enrollment, or over 18 years of age but under medical guardianship;\n* Parent\u002Fguardian screened positive for food insecurity.\\* \\*Assessed through validated 2-item food insecurity screen.\n\nExclusion Criteria:\n\n* Patient received only surgery, or watchful waiting\u002Fsurveillance, for cancer- directed therapy;\n* Foreign national family receiving cancer care as an embassy-pay patient.",{"count":110,"type":21},17,[24],"The goal of the Cardiovascular Health Equity Through Food (CHEF) program is to make it easier for participants and families to cook and eat healthy foods during and following childhood cancer treatment with the long-term goal of supporting heart health.",[114,28],"Childhood Cancer",[116,114,117],"Cardiovascular Health","Childhood Cancer Survivorship","2026-04-08",{"date":120,"type":40},"2026-04-13",{"date":122,"type":40},"2025-04-07",{"date":124,"type":21},"2028-03-30",{"name":126,"class":47},"Dana-Farber Cancer Institute",2,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100623595","schoolcare-a-social-intervention-introducing-telepresence-robots-and-school-navigation-to-reduce-school-fragmentation-for-children-undergoing-cancer-treatment-100623595","NCT07398677","SchoolCare: A Social Intervention Introducing Telepresence Robots and School Navigation to Reduce School Fragmentation for Children Undergoing Cancer Treatment","SchoolCare: A Social Intervention Introducing Telepresence Robots and School Navigation to Reduce School Fragmentation for Children Undergoing Cancer Treatment - Study Protocol of a Multi-Site Randomized Controlled Trial (RCT)","SchoolCare","Children and adolescents are eligible for inclusion if they meet the following criteria: they are: (1) diagnosed with cancer or cancer-like diseases withing two months of inclusion (e.g., benign brain tumors, MDS, or LCH ); (2) have undergone a stem cell transplant, or have experienced cancer relapse or disease progression within the two months of inclusion; (3) aged 5-17 years; (4) admitted to the pediatric oncology ward at Copenhagen University Hospital, Aarhus University Hospital, or Aalborg University Hospital; (5) expected to experience disrupted schooling, defined as absence of more than one school day per week over an anticipated period of eight months; and (6) enrolled, or expected enrolment, in a school in Denmark during the eight month intervention period.\n\nParticipants will be excluded if: (1) the children in intervention arm B obtain a telepresence robot outside of the SchoolCare intervention; (2) the child is unable to communicate in Danish; or (3) the child has physical or cognitive impairments that prevent them from operating or meaningfully engaging with the telepresence robot. Assessment of the latter criterion will be conducted jointly by hospital personnel and the school navigator to determine whether the child is likely to benefit from participation in the intervention. All reasons for exclusion will be documented and reported in accordance with CONSORT guidelines \\[47\\] supplemented by the CONSORT-SPI extended version of social and psychological interventions \\[48\\]. Parents and teachers of the participating children will also be included in the study and invited to complete questionnaires as well as take part in semi-structured interviews. Recruitment began on February 1st, 2026.","5 Years","17 Years",{"count":139,"type":21},128,[24],"Advances in pediatric cancer treatment have led to significant improvements in survival rates, where 5-year survival now exceeds 85%. Despite improved survival, children and adolescents who survive cancer often face significant short- and long-term psychosocial and physical late effects. Children undergoing cancer treatment often experience prolonged school absence, which disrupts their academic development and impedes critical socio-emotional growth during formative school years, with lasting consequences into adulthood. Together, these challenges underscore the need for targeted interventions that support educational continuity, promote school activity, and foster psychosocial well-being.\n\nThe SchoolCare Intervention aims to reduce school absence experienced by children diagnosed with cancer during their treatment trajectory. The intervention introduces school navigation support in combination with the use of telepresence robots (TPRs) and a teleteaching program. TPRs enable the children to attend school remotely, when they are not able to attend physically. The study is designed to investigate the effectiveness of the intervention throughout a period of eight months for school-aged children (i.e., 5-17 years) who are diagnosed with cancer. The investigators hypothesize that telepresence robots will increase school attendance among children and adolescents diagnosed with cancer, representing our primary outcome (H1). Additionally, the investigators explore secondary outcomes by hypothesizing that the intervention will improve the social well-being of these children and adolescents (H2) and enhance their academic level (H3). By focusing on both school attendance and broader psychosocial and academic effects, this study will provide a comprehensive evaluation of the telepresence robot intervention and its potential to support educational continuity and well-being for children with cancer.",[143,144,28,145],"School Attendance","Academic Level","Social Well-being",[143,147,148,149,150,151,152,153],"Social well-being","Robot","Telepresence","Cancer","School","Children","School Navigation","2026-03-17",{"date":156,"type":40},"2026-03-19",{"date":158,"type":40},"2026-02-20",{"date":160,"type":21},"2028-09-30",{"name":162,"class":47},"Rigshospitalet, Denmark",3,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":172,"sex":16,"minAge":173,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100612399","evaluation-of-cardiac-and-endothelial-function-in-children-and-adolescents-treated-with-anthracycline-100612399","NCT07253077","Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline","Evaluation of Cardiac and Endothelial Function Measured by Laboratory Biomarkers and Echocardiographic and Endothelial Testing in Children and Adolescents Treated With Anthracyclines","CARDIO-PED","Inclusion Criteria for the patient group:\n\n* diagnosis of cancer during childhood (diagnosis made between 0 and 16 years of age);\n* age at enrollment greater than or equal to 6 years;\n* having received anthracycline chemotherapy;\n* disease remission for at least 1 year;\n* absence of known cardiac disease prior to anthracycline therapy;\n* absence of congenital heart disease.\n\nExclusion Criteria for the patient group:\n\n* disease remission for less than 1 year;\n* age less than 6 years at the time of enrollment;\n* presence of known comorbidities (cardiopulmonary diseases, neurological diseases, etc.).\n\nInclusion Criteria for the control group:\n\n* age at the time of enrollment: 6 years or older;\n* good health.\n\nExclusion Criteria for the control group:\n\n* having had oncological diseases;\n* having undergone thoracic radiotherapy;\n* having undergone anthracycline chemotherapy;\n* being under 6 years of age at the time of enrollment;\n* having known comorbidities (cardiopulmonary diseases, neurological diseases, etc.).",true,"6 Years","35 Years",{"count":176,"type":21},40,"In recent decades, the survival rate of children with cancer has increased significantly thanks to personalized treatments and the adoption of international therapeutic protocols. However, along with this increase in survival, side effects related to these treatments on various organs and systems have been observed.\n\nAmong the most widely used chemotherapeutic agents in pediatric age, anthracyclines play a crucial role in the treatment of various forms of neoplasms (both haematological such as acute lymphoblastic leukemia or lymphomas, and solid tumors such as sarcomas). However, in addition to their excellent antineoplastic effect, they are burdened by the potential for cardiotoxicity. This cardiotoxicity manifests clinically with left ventricular systolic dysfunction and arrhythmias.\n\nAt the moment, international guidelines recommend long-term cardiac follow-up evaluations for this group of patients, even after treatment has concluded.The methods used in the cardiac follow-up of patients undergoing anthracycline therapy include echocardiography, cardiac magnetic resonance imaging, tests to assess endothelial function, and measurements of the biomarkers troponin and atrial natriuretic peptide. These methods can assess anthracycline-induced cardiac and endothelial damage once it has already occurred, but they cannot predict its onset nor can they study its pathogenesis.\n\nFurthermore, to date, no information is available regarding the possibility of using \"endothelial-mesenchymal transition\" biomarkers as predictors of the onset of anthracycline-induced cardiac damage.\n\nThis study analyzes these biomarkers as predictive tools for cardiac damage. Specifically, plasma levels of Serpin 3, THBS1, TGFbeta1, HIF1a, extracellular ICAM1, troponin, proBNP, fibrinogen, von Willebrand factor, and endothelin will be measured in patients treated with anthracycline. The concentrations of these biomarkers will be compared with the results of the echocardiogram and with the treatments performed in order to identify any relationships. Furthermore, plasma levels of Serpin 3, THBS1, TGFbeta1, HIF1a, extracellular ICAM1, troponin, proBNP, fibrinogen, von Willebrand factor, and endothelin will also be measured in a population of healthy subjects in order to obtain data on a possible relationship between the biomarkers and the anthracycline therapies performed.",[179,180,28],"Anthracycline Related Cardiotoxicity in Childhood Cancers","Chemotherapeutic Toxicity",[182,183,184,185],"Childhood cancer survivors","Anthracycline related cardiotoxicity","Chemotherapy long term side effects","Cancer survivor follow up","2025-11-19",{"date":188,"type":40},"2025-11-28",{"date":190,"type":21},"2025-11",{"date":192,"type":21},"2027-01",{"name":194,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",1,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":212,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":195},"100583170","adapting-the-fear-of-recurrence-therapy-fort-for-parents-and-establishing-acceptability-and-feasibility-100583170","NCT06872840","Adapting The Fear Of Recurrence Therapy (FORT) for Parents and Establishing Acceptability and Feasibility","Addressing Fear of Cancer Recurrence in Parents of Pediatric Cancer Survivors: Adapting The Fear Of Recurrence Therapy (FORT) for Parents and Establishing Acceptability and Feasibility","Parent-FORT","Inclusion Criteria:\n\n* Parent (or primary caregiver) caring for a childhood cancer survivor (\\\u003C18 years of age) of any type of cancer type, who is at least 1 months from the completion of active treatment and has not had a recurrence of their cancer\n* A score of 13 or greater on the Fear of Cancer Recurrence Inventory-Short Form-Parent version (FCRI-SF-P; range 0-36), suggesting clinical levels of FCR\n* Access to a computer and internet connection\n* Living in Canada\n\nExclusion Criteria:\n\n* Being the parent of a pediatric cancer survivor who is now 18 years of age or older\n* Being the parent of a pediatric cancer survivor who has undergone hematopoietic cell transplantation and has active chronic or acute graft-versus-host disease which has not stabilized for at least 3 months\n* Non-English speakers\n* Currently participating in another therapist-led psychosocial therapy group\n* Parent with unmanaged\u002Fundermanaged mental health disorder judged to be clinically contraindicated and\u002For likely to affect the group work\n* To avoid violating the assumption of nonindependence of the data, only one parent\u002Fcaregiver per child can participate in the study.",{"count":205,"type":21},36,[24],"Clinical levels of fear of cancer recurrence (FCR) affect up to 59% of adult cancer survivors. Family caregivers experience equal or greater levels of FCR, which has been linked to lower quality of life and increased distress. FCR can be addressed in cancer survivors with brief interventions. However, none of these interventions have been tested with parents of childhood cancer survivors. This is an urgent gap: the survival rates of childhood cancer have increased more rapidly than for adult cancers, resulting in a growing population of childhood cancer survivors who, along with their families, need support.\n\nThe goals of this pilot study are to demonstrate 1) that a newly adapted intervention of FORT (Parent-FORT) is feasible (i.e., participant recruitment, attendance and participation) and acceptable (i.e., parent satisfaction of the intervention) for a larger study, and 2) the clinical implications of Parent-FORT on fear of cancer recurrence (FCR) and quality of life in parents of childhood cancer survivors.\n\nParents will be randomly assigned to participate in the Parent-FORT intervention immediately or a three-month waitlist control group. They will complete a questionnaire package before and after the intervention, as well as at a three month follow up. This study will help bridge an important gap in bringing evidence-based care to parents who have never been offered help before for their FCR.",[150,209,210,211,28],"Parent","Fear of Cancer Recurrence","CBT",[213,214,215],"Pilot study","Group Therapy","Virtual","2025-09-16",{"date":218,"type":40},"2025-09-22",{"date":220,"type":40},"2025-08-26",{"date":222,"type":21},"2027-05-26",{"name":224,"class":47},"University of Ottawa",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":172,"sex":16,"minAge":173,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":195},"100602218","pain-and-sleep-disturbances-in-children-living-beyond-cancer-a-case-control-study-100602218","NCT07120646","Pain and Sleep Disturbances in Children Living Beyond Cancer: A Case-Control Study","The Co-Morbidity of Pain and Sleep Disturbances in Children Living Beyond Cancer: A Case-Control Study","Inclusion Criteria:\n\n* CBC: 1) current age 6-12yo; 2) history of any cancer diagnosis; 3) ≤ 5y post- treatment completion; 4) ≥ 3 months since last cancer treatment (since pain and insomnia during treatment can be directly related to therapy and recover spontaneously); 5) fluent Dutch speaker and reader (age-dependent)\n* Healthy controls (age- and sex-matched): 1) current age 6-12yo; 2) no history of cancer ; 3) fluent Dutch speaker and reader (age-dependent)\n* Parents: 1) fluent Dutch speaker and reader\n\nExclusion Criteria:\n\n* CBC: 1) receiving palliative therapy; 2) psychiatric disorder; 3) severe intellectual disability\n* Healthy controls: 1) history of cancer; 2) psychiatric disorder; 3) severe intellectual disability","12 Years",{"count":234,"type":21},76,"Children living beyond cancer (CBC) represent a unique and growing population of young people in need of long-term clinical support. Studies suggest that 11-44% of CBC experience chronic pain, negatively impacting a wide range of child biopsychosocial outcomes and creating high financial burden for their families and society. Often comorbid with pain, one of the most chronic and disturbing side effects reported by CBC are sleep disturbances, and in particular, difficulties initiating and maintaining sleep. Indeed, \\>50% of CBC report some form of sleep disturbance even 9 to 15 years after the cancer diagnosis. Much attention has been paid to sleep and pain as independent constructs within pediatric oncology, yet Belgian data is lacking. Additionally, little is known about how these domains interact with one another and subsequent indications for prevention and intervention. Although evidence shows an interrelationship between pain and sleep in adult and pediatric populations, this interrelationship is understudied in childhood cancer patients and CBC. (Chronic) pain may serve as a modifiable target for interventions to improve sleep quality and vice versa, and understanding this relationship is crucial for providing comprehensive care to CBC. Therefore, this cross-sectional case-control study aims to explore the differences in pain and sleep disturbances in CBC compared to healthy age- and sex-matched healthy controls, as well as the interrelationship between both outcomes.",[28],[238,239,240,241],"children living beyond cancer","pain","sleep disturbances","case-control","2025-08-11",{"date":244,"type":40},"2025-08-13",{"date":246,"type":21},"2025-08",{"date":248,"type":21},"2026-06",{"name":250,"class":47},"Vrije Universiteit Brussel",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":172,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":258,"targetDuration":260,"studyType":85,"phases":4,"briefSummary":261,"conditions":262,"keywords":293,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":195},"100474891","inadvance-surveillance-prevention-and-interception-in-a-population-at-risk-for-cancer-100474891","NCT05463796","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer","Inclusion Criteria:\n\n* Participants to be included in this study include the following (note that this list is not comprehensive but gives examples of precursor conditions for each organ type):\n\n  1-Hereditary risk for cancer including\n  * Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes\n  * Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing)\n  * Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)\n  * Hereditary Cancer Prediction Model-based elevated cancer risk\n  * Others at risk for specific cancers by virtue of exposure, obesity, gender, race and ethnicity, HPV exposure (for H\\&N cancer for example), etc.\n* Exposed High Risk including\n\n  * Childhood cancer survivors with treatment exposures associated with increased risk of cancer\n  * Adult cancer survivors with treatment exposures associated with increased risk of cancer\n  * Documented high level exposure to group 1 IARC carcinogens\n  * Thoracic: individuals at risk for lung cancer including but not exclusive of the following criteria: Age \\>50, Smoking history of \\>15 pack years, First-degree relative history of lung cancer or COPD\n  * alcoholic liver disease (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis\n* Precursor Lesions including\n\n  * Breast: ductal\u002Flobular carcinoma in situ (CIS) and atypical hyperplasia\n  * GI: Barrett's esophagus, Pancreatic precursor lesions, colonic dysplasia\u002Fadenomata, nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis\n  * GU: High grade prostatic epithelial neoplasia, and high-grade bladder urothelial dysplasia\u002Fcarcinoma in situ,\n  * Lung: Adenomatous hyperplasia\n  * H\\&N: high-risk oral precancerous diseases\n  * Skin: Class II melanocytic lesions. Squamous dysplasia\n  * Heme malignancies: CHIP, CCUS, ICUS, MGUS, SMM, SWM, MBL (spell these out), Low grade lymphomas\n  * Thoracic: Lung nodules detected on screening CT that prompt further follow-up\n  * GYN: STIC lesion (serous tubal intraepithelial carcinoma), Endometrial intraepithelial neoplasia, Cervical and endocervical carcinoma in situ, vulvar intraepithelial neoplasia\n  * Pediatric histologic diagnoses sometimes associated with development of malignancy: Nephrogenic rests, benign bone lesions with risk of malignant degeneration (Giant cell tumor, osteochondroma), Spitz nevus, and others.\n* FAMILY MEMBERS or healthy individuals\n\nExclusion Criteria:\n\nThere are no exclusion criteria for the study.\n\nNote: Patients with prior cancer history are allowed to participate. Patients with prior history of cancer or non-metastatic localized cancers (such as skin cancer or localized prostate cancer) are allowed to be enrolled. Patients enrolled in clinical trials or receiving therapy for precursor diseases are NOT excluded from this study.",{"count":259,"type":21},5000,"20 Years","This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer.\n\n* The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.\n* The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.",[263,264,265,28,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292],"Cancer Risk","Cancer Predisposition Syndrome","Hereditary Cancer Prediction","Adult Cancer Survivors","IARC Carcinogens","Smoking History","Lung Cancer","Ductal\u002FLobular Carcinoma","Barrett Esophagus","Pancreatic Precursor Lesions","Colonic Dysplasia\u002FAdenomata","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Steatohepatitis","Cirrhosis","High Grade Prostatic Epithelial Neoplasia","High-grade Bladder Urothelial Dysplasia\u002FCarcinoma in Situ","Adenomatous Hyperplasia","High-risk Oral Precancerous Diseases","Melanocytic Lesion, Adult","Hematologic Malignancy","Lung; Node","Serous Tubal Intraepithelial Carcinoma","Endometrial Intraepithelial Neoplasia","Cervical and Endocervical Carcinoma in Situ","Vulvar Intraepithelial Neoplasia","Nephrogenic Rests","Benign Bone Lesions With Risk of Malignant Degeneration","Giant Cell Tumor","Osteochondroma","Spitz Nevus",[294,182,295,296],"Hereditary Risk for Cancer","Adult cancer survivors","Precursor Lesions","2025-08-04",{"date":299,"type":40},"2025-08-07",{"date":301,"type":40},"2023-04-25",{"date":303,"type":21},"2032-03-25",{"name":126,"class":47},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":313,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":318,"conditions":319,"keywords":323,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":4},"100596244","online-physical-activity-and-health-counseling-for-survivors-of-childhood-acute-lymphoblastic-leukemia-100596244","NCT07042932","Online Physical Activity and Health Counseling for Survivors of Childhood Acute Lymphoblastic Leukemia","Online Physical Activity and Health Counseling for Survivors of Childhood Acute Lymphoblastic Leukemia (OPAC-ALL)","OPAC-ALL","Inclusion Criteria:\n\n* aged 10-21 years old,\n* at least one year from ended treatment of acute lymphoplastic leukemia\n* not adhering to WHO's recommendations for physical activity (i.e., 60 minutes of daily moderate-to-vigorous intensity physical activity including two weekly sessions of strength training for children and 150 minutes of moderate-to-vigorous intensity weekly for adults),\n* followed at the pediatric oncology out-patient clinic at Copenhagen University Hospital, Rigshospitalet.\n\nExclusion Criteria:\n\n* Children with a mental disability,\n* other severe physical co-morbidity contradicting physical exercise,\n* and\u002For terminal illness","10 Years","21 Years",{"count":316,"type":21},82,[24],"Advances in the medical treatment of childhood acute lymphoblastic leukemia (ALL) have resulted in 5-year survival rates above 90%- however, the success is not without consequences. Childhood ALL survivors experience markedly impaired physical capacity - reducing their opportunity to engage in everyday activities including leisure activities, sports, and school - affecting their quality of life. Furthermore, Childhood ALL survivors have markedly increased risk of chronic medical conditions including cardiometabolic diseases - that can be prevented through an active lifestyle. Thus, it is imperative to develop novel interventions that can mitigate these treatment-related late-effects. In this RCT, including 82 childhood ALL survivors (10-21 years-old), we will investigate a 26-week online exercise intervention combined with access to a lifestyle physical activity webpage, and health consultations on cardiorespiratory fitness (primary outcome) markers of metabolic syndrome, and physical activity habits.\n\nWhile other pilot studies have investigated the effects of exercise for childhood ALL survivors, this study is the first RCT internationally to investigate the effects of online exercise combined with education through an app and health counselling for childhood ALL survivor. Using this approach, we are geographically able to reach every survivor in our targeted population, thereby, minimizing logistic challenges like travel distances.\n\nThis study has the potential to radically change the way physical rehabilitation is approached in childhood ALL survivors - Potentially changing the workflow of health professionals from referring only survivors with specific deficits to local physiotherapy to referring all survivors to an exercise program tailored to their needs. By improving the children's general physical capacity, we can give the children the required tools to re-enter everyday life activities, including school physical education, leisure activities, and sports earlier after treatment has ended - ultimately minimizing the social complications of treatment. This study will also answer the government´s call to digitalize 30% of rehabilitation by the 2030.",[320,28,321,322],"Acute Lymphoblastic Leukemia ALL","Exercise","Rehabilitation Exercise",[321,324,325,92],"rehabilitation","Acute lymphoblastic leukemia","2025-06-25",{"date":328,"type":40},"2025-06-29",{"date":330,"type":21},"2025-07-01",{"date":332,"type":21},"2030-12-31",{"name":162,"class":47},{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":172,"sex":342,"minAge":56,"maxAge":343,"enrollmentInfo":344,"targetDuration":346,"studyType":85,"phases":4,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":163},"100564215","fertility-and-ovarian-reserve-in-female-childhood-cancer-survivors-100564215","NCT06626282","Fertility and Ovarian Reserve in Female Childhood Cancer Survivors","PReserving Fertility and Quality of Life IN Belgian Female Paediatric CancEr SurvivorS","PRINCESS","Inclusion Criteria:\n\n* Child and adolescent female patients included in the Paediatrics Late Effects Project:\n* diagnosed with cancer1 between 01\u002F01\u002F2004 and 31\u002F12\u002F2018\n* \\\u003C17 years old at diagnosis\n* treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF\n* alive\n* ≥ 18 years-old at time of recruitment.\n\nExclusion Criteria:\n\n* Cancer diagnosis for controls","FEMALE","50 Years",{"count":345,"type":21},340,"3 Months","Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. We propose to identify new epigenetic markers in order to predict the risk of premature ovarian insufficiency. The project will be led by a national multi-disciplinary team (paediatric oncologists, gynaecologists, endocrinologists). Paediatric cancer clinical data (therapy, fertility preservation, ...) will be extracted from the Paediatrics Late Effects database and additional data will be collected during PRINCESS fertility evaluation. Through translational and multi-disciplinary approaches, results should improve quality of life and fertility preservation in female survivors of paediatric cancer by developing new personalised screening tools for premature ovarian insufficiency.",[28,349,350,351,352,353,354,355],"Fertility","Ovarian Reserve","CED","Ovarian Reserve Markers","Cryopreservation","Alkylating Agents","Female","2024-10-30",{"date":358,"type":40},"2024-11-01",{"date":360,"type":40},"2024-10-09",{"date":362,"type":21},"2028-12-31",{"name":364,"class":47},"Centre Hospitalier Universitaire de Liege"]